Sharmila Dorbala, MD, MPH, FASNC, Chair*; Yukio Ando, MD, PhD†; Sabahat Bokhari,
MD‡; Angela Dispenzieri, MD § ; Rodney H. Falk, MD*; Victor A. Ferrari, MD∥; Marianna …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive,
infiltrative disease caused by the deposition of transthyretin amyloid fibrils in the heart, and …

Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the
monitoring of heart transplant (HTx) rejection. In addition, EMB can have an important …

Importance Many patients with systemic amyloidosis are underdiagnosed. Overall, 25% of
patients with immunoglobulin light chain (AL) amyloidosis die within 6 months of diagnosis …

Cardiac amyloidosis (CA), once thought to be a rare disease, is increasingly recognized due
to enhanced clinical awareness and better diagnostic imaging. CA is becoming of …

In this update, we focus on selected topics of high clinical relevance for health care
providers who treat patients with heart failure (HF), on the basis of clinical trials published …

Amyloid light chain (AL) amyloidosis is among the more common and more severe of the
amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell …

Purpose Cardiac transthyretin-related amyloidosis (ATTR) is a progressive and fatal
cardiomyopathy. The diagnosis of this disease is frequently delayed or missed due to the …

Abstract Purpose of Review Heart failure with preserved ejection fraction (HFpEF) is a
relatively new disease entity used in medical terminology; however, both the number of …

The prevalence and significance of cardiac amyloidosis have been considerably
underestimated in the past; however, the number of patients diagnosed with cardiac …